Pro Dex Inc PDEX
We take great care to ensure that the data presented and summarized in this overview for PRO DEX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PDEX
Top Purchases
Top Sells
About PDEX
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Insider Transactions at PDEX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 25
2024
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+0.32%
|
$640
$16.22 P/Share
|
|
Jul 01
2024
|
Alisha Charlton Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,938
-19.42%
|
$70,884
$18.35 P/Share
|
|
Jul 01
2024
|
Alisha Charlton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,800
+34.75%
|
-
|
|
Jul 01
2024
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
5,237
+5.03%
|
$94,266
$18.35 P/Share
|
|
Jul 01
2024
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,800
+12.46%
|
-
|
|
Jul 01
2024
|
Angelita Rebamontan Domingo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,594
-17.3%
|
$46,692
$18.35 P/Share
|
|
Jul 01
2024
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+31.21%
|
-
|
|
Jun 24
2024
|
Angelita Rebamontan Domingo Director |
SELL
Open market or private sale
|
Direct |
2,585
-23.99%
|
$46,530
$18.3 P/Share
|
|
Jan 25
2024
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.32%
|
$630
$18.32 P/Share
|
|
Jul 27
2023
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
41
+0.38%
|
$615
$15.82 P/Share
|
|
Jul 27
2023
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
493
+0.55%
|
$7,395
$15.82 P/Share
|
|
Jan 26
2023
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
43
+0.4%
|
$602
$14.79 P/Share
|
|
Jan 26
2023
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
527
+0.59%
|
$7,378
$14.79 P/Share
|
|
Dec 08
2022
|
David Hovda Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+39.47%
|
$3,000
$2.14 P/Share
|
|
Aug 30
2022
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.37%
|
$5,000
$1.73 P/Share
|
|
Jul 28
2022
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
577
+0.69%
|
$7,501
$13.52 P/Share
|
|
Jul 28
2022
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
30
+0.28%
|
$390
$13.52 P/Share
|
|
Jul 14
2022
|
Richard Lee Van Kirk Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,094
-5.81%
|
$81,504
$16.09 P/Share
|
|
Jul 14
2022
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,800
+14.44%
|
-
|
|
Jul 14
2022
|
Angelita Rebamontan Domingo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,232
-17.38%
|
$35,712
$16.09 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 32.5K shares |
|---|---|
| Payment of exercise price or tax liability | 5.24K shares |
| Payment of exercise price or tax liability | 6.53K shares |
|---|---|
| Open market or private sale | 2.59K shares |